Announcement Information

Num| Date| Title| Submitter
10 2021.01.29 Resolutions for Convocation of General Meeting of Shareholders Aptabio Therapeutics Inc.
9 2021.01.29 30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations) Aptabio Therapeutics Inc.
8 2020.12.31 Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 신청) Aptabio Therapeutics Inc.
7 2020.12.11 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제(Therapeutic Agent For Liver Disorder)) Aptabio Therapeutics Inc.
6 2020.12.09 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(안질환 치료용 조성물) Aptabio Therapeutics Inc.
5 2020.08.20 Additional Listing(주식매수선택권행사) Aptabio Therapeutics Inc.
4 2020.08.03 Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) Aptabio Therapeutics Inc.
3 2020.06.19 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물) Aptabio Therapeutics Inc.
2 2020.06.12 Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) Aptabio Therapeutics Inc.
1 2020.06.10 Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) Aptabio Therapeutics Inc.
2021.01.29 Aptabio Therapeutics Inc.
Resolutions for Convocation of General Meeting of Shareholders
2021.01.29 Aptabio Therapeutics Inc.
30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)
2020.12.31 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 신청)
2020.12.11 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제(Therapeutic Agent For Liver Disorder))
2020.12.09 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(안질환 치료용 조성물)
2020.08.20 Aptabio Therapeutics Inc.
Additional Listing(주식매수선택권행사)
2020.08.03 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
2020.06.19 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물)
2020.06.12 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
2020.06.10 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)